You are here

Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos

Last updated on December 5, 2018

FOR MORE INFORMATION
Study Location
Private Clinic
Lipa City, Batangas, Philippines
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Disease
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6 + weeks
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

Patients prescribed with the vaccine

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

Patients with hypersensitivity to the vaccine

NCT01396434
Pfizer
Completed
Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos
A Non-interventional Study Of The Safety Of Pneumococcal 13-valent Conjugate Vaccine (Prevenar 13) In The Philippines: A Post Marketing Surveillance Study
Prevenar 13 is safe for administration to Filipinos.
Filipino patients prescribed and administered with the vaccine will be monitored for safety Patients prescribed with the vaccine who provides consent for inclusion to the study will be observed.
Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Filipino patients prescribed with the vaccine
Pneumococcal Disease
Biological: Prevenar 13
Prevenar 13 vaccine as prescribed by the physician based on approved product indication
Other Name: Pneumococcal 13-valent Conjugate Vaccine (13vPnC)
Prevenar 13 patients
Intervention: Biological: Prevenar 13
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3006
May 2014
May 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

Patients prescribed with the vaccine

Exclusion Criteria:

Patients with hypersensitivity to the vaccine

Sexes Eligible for Study: All
6 Weeks and older   (Child, Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Philippines
 
 
NCT01396434
B1851076
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
January 2016

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now